<it>KRAS </it>rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study
<p>Abstract</p> <p>Background</p> <p>A single nucleotide polymorphism located in the 3'-untranslated region of the <it>KRAS </it>oncogene (<it>KRAS </it>variant; rs61764370) disrupts a let-7 miRNA binding and was recently reported to act as...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-03-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://www.biomedcentral.com/1471-2407/12/105 |
| _version_ | 1818551714178924544 |
|---|---|
| author | Cerne Jasmina-Ziva Stegel Vida Gersak Ksenija Novakovic Srdjan |
| author_facet | Cerne Jasmina-Ziva Stegel Vida Gersak Ksenija Novakovic Srdjan |
| author_sort | Cerne Jasmina-Ziva |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>A single nucleotide polymorphism located in the 3'-untranslated region of the <it>KRAS </it>oncogene (<it>KRAS </it>variant; rs61764370) disrupts a let-7 miRNA binding and was recently reported to act as a genetic marker for increased risk of developing human cancers. We aimed to investigate an association of the <it>KRAS </it>variant with sporadic and familial breast cancer and breast tumor characteristics.</p> <p>Methods</p> <p>Genotyping was accomplished in 530 sporadic postmenopausal breast cancer cases, 165 familial breast cancer cases (including N = 29, who test positive for <it>BRCA1/2 </it>mutations) and 270 postmenopausal control women using the flurogenic 5' nuclease assay. Information on hormone replacement therapy (HRT) use and tumor characteristics in sporadic breast cancer cases was ascertained from a postal questionnaire and pathology reports, respectively. Associations between the <it>KRAS </it>genotype and breast cancer or breast tumor characteristics were assessed using chi-square test and logistic regression models.</p> <p>Results</p> <p>No evidence of association was observed between the <it>KRAS </it>variant and risk of sporadic and familial breast cancer - either among <it>BRCA </it>carriers or non-<it>BRCA </it>carriers. The <it>KRAS </it>variant was statistically significantly more often associated with human epidermal growth factor receptor 2 (HER2) - positive tumors and tumors of higher histopathologic grade. However, both associations were detected only in HRT users.</p> <p>Conclusion</p> <p>Our data do not support the hypothesis that the <it>KRAS </it>variant rs61764370 is implicated in the aetiology of sporadic or of familial breast cancer. In postmenopausal women using HRT, the <it>KRAS </it>variant might lead to HER2 overexpressed and poorly-differentiated breast tumors, both indicators of a worse prognosis.</p> |
| first_indexed | 2024-12-12T09:03:34Z |
| format | Article |
| id | doaj.art-39dec1c93b51468bacd3f2c8daf05d05 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-12T09:03:34Z |
| publishDate | 2012-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-39dec1c93b51468bacd3f2c8daf05d052022-12-22T00:29:44ZengBMCBMC Cancer1471-24072012-03-0112110510.1186/1471-2407-12-105<it>KRAS </it>rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control studyCerne Jasmina-ZivaStegel VidaGersak KsenijaNovakovic Srdjan<p>Abstract</p> <p>Background</p> <p>A single nucleotide polymorphism located in the 3'-untranslated region of the <it>KRAS </it>oncogene (<it>KRAS </it>variant; rs61764370) disrupts a let-7 miRNA binding and was recently reported to act as a genetic marker for increased risk of developing human cancers. We aimed to investigate an association of the <it>KRAS </it>variant with sporadic and familial breast cancer and breast tumor characteristics.</p> <p>Methods</p> <p>Genotyping was accomplished in 530 sporadic postmenopausal breast cancer cases, 165 familial breast cancer cases (including N = 29, who test positive for <it>BRCA1/2 </it>mutations) and 270 postmenopausal control women using the flurogenic 5' nuclease assay. Information on hormone replacement therapy (HRT) use and tumor characteristics in sporadic breast cancer cases was ascertained from a postal questionnaire and pathology reports, respectively. Associations between the <it>KRAS </it>genotype and breast cancer or breast tumor characteristics were assessed using chi-square test and logistic regression models.</p> <p>Results</p> <p>No evidence of association was observed between the <it>KRAS </it>variant and risk of sporadic and familial breast cancer - either among <it>BRCA </it>carriers or non-<it>BRCA </it>carriers. The <it>KRAS </it>variant was statistically significantly more often associated with human epidermal growth factor receptor 2 (HER2) - positive tumors and tumors of higher histopathologic grade. However, both associations were detected only in HRT users.</p> <p>Conclusion</p> <p>Our data do not support the hypothesis that the <it>KRAS </it>variant rs61764370 is implicated in the aetiology of sporadic or of familial breast cancer. In postmenopausal women using HRT, the <it>KRAS </it>variant might lead to HER2 overexpressed and poorly-differentiated breast tumors, both indicators of a worse prognosis.</p>http://www.biomedcentral.com/1471-2407/12/105<it>KRAS </it>rs61764370Breast cancerTumor characteristicsHormone replacement therapy |
| spellingShingle | Cerne Jasmina-Ziva Stegel Vida Gersak Ksenija Novakovic Srdjan <it>KRAS </it>rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study BMC Cancer <it>KRAS </it>rs61764370 Breast cancer Tumor characteristics Hormone replacement therapy |
| title | <it>KRAS </it>rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study |
| title_full | <it>KRAS </it>rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study |
| title_fullStr | <it>KRAS </it>rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study |
| title_full_unstemmed | <it>KRAS </it>rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study |
| title_short | <it>KRAS </it>rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study |
| title_sort | it kras it rs61764370 is associated with her2 overexpressed and poorly differentiated breast cancer in hormone replacement therapy users a case control study |
| topic | <it>KRAS </it>rs61764370 Breast cancer Tumor characteristics Hormone replacement therapy |
| url | http://www.biomedcentral.com/1471-2407/12/105 |
| work_keys_str_mv | AT cernejasminaziva itkrasitrs61764370isassociatedwithher2overexpressedandpoorlydifferentiatedbreastcancerinhormonereplacementtherapyusersacasecontrolstudy AT stegelvida itkrasitrs61764370isassociatedwithher2overexpressedandpoorlydifferentiatedbreastcancerinhormonereplacementtherapyusersacasecontrolstudy AT gersakksenija itkrasitrs61764370isassociatedwithher2overexpressedandpoorlydifferentiatedbreastcancerinhormonereplacementtherapyusersacasecontrolstudy AT novakovicsrdjan itkrasitrs61764370isassociatedwithher2overexpressedandpoorlydifferentiatedbreastcancerinhormonereplacementtherapyusersacasecontrolstudy |